However, since this novel therapy has never been applied to the most difficult cancers such as triple negative breast cancer, the aim of this study was to evaluate the therapeutic potential of the IFNβ-hUCMSCs for treating triple negative breast carcinomas. Here, IFNB1 is linked to triple-negative breast carcinoma.